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A new compound, 4-hydroxyheptachlorostyrene (4-OH-
HpCS), was identified as a major component in the chlorinated
phenolic compound fraction of polar bear plasma. The
structure was hypothesized to be 4-OH-HpCS based on mass
spectral interpretation, the assumption that it was a
metabolite of octachlorostyrene, and the similarity of the
structure to hydroxylated polychlorinated biphenyls (OH-PCBs)
identified in plasma. High-resolution, electron impact (EI)
ionization mass spectrometry of the methylated compound
indicated a molecular formula of C9H3OCl7 and major
fragment ions of [M - 15]+, [M - 35]+, and [M - 43]+,
which was a mass spectral pattern identical to a synthesized
and methylated 4-OH-HpCS standard. The identity was
further confirmed by matching gas chromatography (GC)
retention times on three different GC columns of differing
polarity. Levels of 4-OH-HpCS ranged from 2.89 to 22.9
ng/g wet weight in polar bear plasma (N ) 30) and constituted
between 3.8 and 24.8% of the total quantified level of
chlorinated phenolic compounds. The mean ratio of 4-OH-
HpCS to CB153 concentrations in polar bear plasma
samples was 0.712 (( 0.580 SD), which suggests selective
retention of the 4-OH-HpCS in plasma. The presumed
mechanism of retention involves 4-OH-HpCS binding to
transthyretin (TTR). The presence of TTR was confirmed
for the first time in polar bear plasma by binding of 125I-
thyroxine (T4), the natural ligand of TTR, to separated
plasma proteins. The binding affinity of 4-OH-HpCS to human
TTR was tested and found to be 1.1 relative to T4. This
suggests that 4-OH-HpCS has the potential to disrupt T4 and
retinol transport, by analogy to OH-PCBs with similar
structure. Metabolism of octachlorostyrene (OCS) is the
most likely source of 4-OH-HpCS. OCS was shown to be
present at low concentrations in polar bear tissues as well
as in plasma of ringed seal, the principal prey species
of polar bears. The ratio of 4-OH-HpCS to OCS and 4-OH-
HpCS to CB153 concentrations were 150- and 44-fold
higher in polar bear plasma than in ringed seal plasma.
This study indicates that the phenolic metabolites of relatively
minor contaminants possess the capacity to bind to
circulating proteins, and their significance as potential
endocrine-disrupting agents may be underestimated.
Introduction
Polyhalogenated aromatic hydrocarbons (PHAHs) have been
studied extensively due to their ubiquitous presence in biota.
Phenolic metabolites of PHAHs isolated from plasma have
received particular interest (1). Phenolic compounds are
capable of modulating hormone-mediated processes in vitro
and in vivo, via processes dependent on the estrogen receptor
(2), and the disruption of thyroid hormone (3) and vitamin
A transport (4). For example, OH-PCBs, phenolic metabolites
formed in wildlife and humans and retained in plasma (5,
6), have demonstrated potential estrogenic activity (7) but
especially thyroidogenic effects in vitro and in vivo (8).
The prohormone, T4, is transported to target tissues by
thyroid hormone transport proteins, such as TTR. The
deiodinase family of enzymes present in these target tissues
converts T4 to the active hormone, triiodothyronine (T3) (9).
Aromatic compounds that have OH-groups with adjacent
halogen substituents can bind with high affinity to TTR (8).
The binding potency of pentachlorophenol (PCP) and 4'-
OH-3,3',4,5'-tetrachlorobiphenyl toward TTR was 2 and
4 times greater, respectively, than the natural hormone, T4
(10,11). Hydroxylated polybrominated diphenyl ethers (OH-
PBDEs) with T3- and T4-like structures (i.e. bromine atoms
adjacent to the phenolic OH-group) have been reported to
bind to the human R- and â-thyroid hormone receptor (12)
and compete with T4 for binding with TTR in vitro (13).
Biotransformation has been shown to generate other
phenolic compounds that may be capable of binding to TTR.
In rats, hexachlorobenzene is biotransformed in vivo to PCP
(14), and OCS is converted to a heptachloro metabolite and
a pentachlorophenyldichloroacetic acid metabolite (15). The
presence of a heptachloro metabolite suggests that the
pathway for biotransformation of OCS may be via dechlo-
rination and possibly hydroxylation.
Polar bears are the top predators in the arctic marine
food chain, eating primarily ringed seal. Consequently, they
bioaccumulate high concentrations of several PHAHs, most
notably polychlorianted biphenyls (PCBs) and methylsul-
fonyl-PCBs (16-18). Thus, polar bears are an important
biomonitoring species of PHAH exposure in the arctic (17).
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The high body burden of contaminants can induce enzymes
of the hepatic cytochrome P450 system, which are responsible
for the metabolism of both endogenous compounds and
xenobiotics (19). The polar bear has demonstrated a high
capability to metabolize several PHAHs, including 4,4′-DDE
and many PCB congeners (20). It is reasonable to suppose
that persistent OH-PCB metabolites would be formed in polar
bear, as has been found for other mammals (6) and humans
(5). Therefore, a study was initiated to examine the presence
and identity of OH-PCBs in polar bear plasma and their
possible effects on circulating vitamin A and thyroid hormone
levels. The results of this study will be reported elsewhere.
During methodological development for the extraction
and quantification of OH-PCBs, an unknown phenolic
compound was detected in polar bear plasma (21). The
unknown compound was frequently the major peak in the
methylated phenolic compound fraction chromatogram.
We report on the identification of the unknown phenolic
compound in polar bear plasma, which we hypothesized to
be a hydroxylated metabolite of OCS based on preliminary
mass spectral evidence. The identification involved the bulk
extraction of polar bear plasma and purification of the
unknown compound for mass spectral analysis using high
and low-resolution mass spectrometry. The hypothesized
compound was then synthesized. Comparisons of the mass
spectra and gas chromatographic retention times on three
GC columns with varying polarities were used to determine
if the synthesized compound was the hypothesized phenolic
OCS metabolite. To attempt to resolve the significance of
biotransformation as a source of this phenolic compound in
the polar bear, its concentration and the concentration of
OH-PCBs, OCS, and PCBs were determined in polar bear
and ringed seal plasma. OCS and PCBs in polar bear adipose
tissue and liver were also quantitated. The presence of TTR
in polar bear plasma was determined by polyacrylamide gel
electrophoresis (PAGE) separation of proteins and protein
binding of 125I-labeled T4. High affinity binding to TTR is the
presumed mechanism of selective retention of phenolic
compounds in plasma (8). A competitive binding assay using
purified human TTR and 125I-labeled T4 was used to study
the TTR binding affinity of the phenolic OCS metabolite
relative to the natural thyroid hormone, T4.
Materials and Methods
Samples. Polar bear plasma samples used in this study were
collected from 30 polar bears captured between April and
May 1997 by Dr. Malcolm Ramsay (University of Saskatche-
wan, Saskatoon, SA) around the Resolute Bay area (Nunavut
Territory, Canada). Whole blood was drawn into 50 mL
heparinized vacutainers and stored on ice and out of light
until processed. Blood samples were centrifuged, and the
plasma was drawn off, frozen at -40 °C, and stored until
further analysis.
Plasma samples (N ) 5) from ringed seal (age and gender
unknown), the main prey species of the polar bear, were
similarly collected in 1999 from around Kuujjuaq, QueÂbec
by Inuit hunters (Anguvigaq Hunting, Trapping and Fishing
Association, Kuujjuaq, QueÂbec) and organized by Daniel
Leclair (Nunavik Research Centre, Makivik Corporation,
Kuujjuaq, QueÂbec). The plasma samples were stored frozen
at -40 °C until analysis.
Polar bear adipose tissue and liver samples (N ) 8) were
collected by Dr. Malcolm Ramsay (University of Saskatche-
wan, Saskatoon, SA) in legally controlled hunts by Inuit in
the Canadian Arctic during the spring of 1992, 1993, and
1994 near Resolute Bay, Nunavut Territory. Details of the
sampling and sample preparation are given by Letcher et al.
(19, 20).
Contaminant Analysis. Prior to extraction, polar bear and
ringed seal plasma samples were spiked with the following
mixture of 13C12-labeled OH-PCBs standards acquired from
Wellington Laboratories (Guelph, ON, Canada): 4'-OH-
2,3',4,5,5'-pentachlorobiphenyl, 4'-OH-2,3,3',4,5,5'-hexachlo-
robiphenyl, 4'-OH-2,2',3,3',4,5,5'-heptachlorobiphenyl, and
4-OH-2,2',3,4',5,5',6-heptachlorobiphenyl (20 íL at 100 pg/
íL). PCP (13C6) (20 íL at 100 pg/íL) and 13C12-CB28, 52, 118,
153, 180, and 194 (10 íL at 2.0 ng/íL) (Cambridge Isotope
Laboratories, Andover, MA) were also added to the plasma
samples. The 13C-labeled standards served as recovery
standards.
The plasma samples were extracted using the method
described by Hovander et al. (22) as modified by Sandau et
al. (5). A performance standard, 4'-Me-4-MeO-2,3,3',5,6-
pentachlorobiphenyl (10 íL at 1.0 ng/íL), was added to all
phenolic fractions, and 13C12-CB138 (10 íL at 4.0 ng/íL) was
added to all neutral fractions prior to mass spectral analysis.
The final volume of both fractions was 200 íL.
OH-PCBs and PCP were quantified by GC-electron capture
negative ionization mass spectrometry (ECNI-MS) employing
authentic standards when available or by using group
response factors for unidentified compounds as described
previously (5). PCBs were quantitated by GC-electron impact
ionization mass spectrometry (EI-MS) using a characterized
secondary polar bear quantitation standard (PBQ) (17).
Concentrations of 4-OH-HpCS were determined separately
by GC equipped with an electron capture detector (ECD)
using a calibration curve of authentic standard and a response
factor relative to the performance standard.
The three types of GC columns used in this study were
as follows: DB-5 ([5%-phenyl]methylpolysiloxane from J&W
Scientific Inc., Folsom, CA, 30 m  0.25 mm i.d., 0.25 ím film
thickness), DB-1701 ([14% cyanopropylphenyl]methylpol-
ysiloxane from J&W Scientific Inc., Folsom, CA, 30 m  0.25
mm i.d., 0.25 ím film thickness), and Rtx-2330 ([90%
biscyanopropyl-10% cyanopropylphenyl]polysiloxane from
Restek Corporation, Bellefonte, PA, 30 m  0.25 mm i.d.,
0.20 ím film thickness).
GC-ECD was performed on a Hewlett-Packard (Palo Alto,
CA) 5890 instrument equipped with an HP7673A automatic
injector, DB-5 column, and a 63Ni ECD detector. The carrier
gas was helium set with a head pressure of 80 kPa, and the
ECD makeup gas was 5% methane-95% argon. All injections
were 2 íL in volume and made in splitless mode. The GC
temperature program was as follows: 80 °C for 2 min, ramp
10 °C/min to 250 °C hold for 5 min, then 5 °C/min to 300
°C. The injector port and interface temperatures were 250
and 280 °C, respectively.
GC-MS (low-resolution fullscan) analysis was performed
with a Hewlett-Packard 5987B instrument. For fullscan ECNI
mode, the GC and MS conditions are described in detail
elsewhere (5). Methane (99.99% pure) was the reagent gas
at a source pressure of 2.5  10-4 Torr. The source
temperature was 140 °C. For EI mode, the source temperature
was set at 120 °C and the electron energy was 70 eV. Fullscan
spectra for the ECNI and EI modes were obtained from 75
to 650 and 250 to 600 amu, respectively.
High-resolution spectra were obtained with a VG AutoSpec
double-focusing mass spectrometer (resolution 10 000) in
fullscan EI mode. The instrumental conditions are described
in Tittlemier et al. (23).
Isolation and Mass Spectral Characterization of the
Unknown Chlorinated Phenolic Compound. To obtain clean
fullscan spectra, a large pooled sample of polar bear plasma
(65 g) from three bears was prepared. The plasma was
extracted, and the phenolic compounds were isolated as
described above. The OH-containing compounds were
methylated to their corresponding methoxy-derivatives by
treatment with diazomethane (24). After further clean up
steps, which included gel permeation chromatography,
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multiple sulfuric acid partitioning (22), silica:sulfuric acid
column treatment (5), and florisil column chromatography
(25), the methylated unknown compound was isolated by
applying the methylated fraction to a florisil column (8.0 g,
1.2% deactivated) and eluting with hexanes. Fractions of 5
mL were collected and analyzed for the presence of the
unknown compound using GC-ECD as described above.
Fractions from 10 to 25 mL contained the majority of the
unknown compound. These were pooled and concentrated
for analysis using both high- and low-resolution fullscan mass
spectrometry.
The methylated phenolic compound fraction was initially
analyzed using GC/ECNI-MS because of interfering biogenic
residue still present following the initial extraction procedure
(5). Interferences were minimized using ECNI since biogenic
compounds generally have low electron-capturing capability
compared to halogenated compounds. A GC/ECNI-MS
chromatogram of the methylated phenolic compound frac-
tion of a polar bear plasma sample is shown in Figure 1. In
addition to several OH-PCB congeners, there was a large
unknown compound eluting nearly 3.5 min after PCP and
about 3.5 min before the first eluting OH-PCB. The retention
time indicated that the compound could either be a
chlorinated monocyclic aromatic compound with a side chain
or a lower chlorinated OH-PCB.
The ECNI spectrum of the methylated unknown phenolic
compound is shown in Figure 2a. The base peak at 322 amu
had an isotope pattern indicative of a hexachlorinated species.
There was only one detectable isotope cluster at higher mass
(338 amu). The 338 amu isotope cluster was also characteristic
of a compound or fragment with six chlorines and must
contain a methoxy group because only methylated phenolic
compounds are present in this fraction. The formula best
matching this fragment was [C9H4Cl6O]-, suggesting that the
unknown compound was most likely a monocyclic aromatic
compound with a side chain. Although this formula was
consistent with a methoxyhexachlorostyrene (MeO-HxCS),
loss of [M - 16]- to form the fragment at 322 amu was unlikely
even though addition of H¥ (i.e. [M - CH3 + H]-) to molecular
and fragment ions frequently occurs in ECNI-MS (26).
Therefore, MeO-heptachlorostyrene (MeO-HpCS, no mo-
lecular ion) or MeO-hexachlorostyrene (MeO-HxCS) isomers
were consistent with the ECNI spectrum. No significant low-
mass fragments were detected, and no other significant
structural information could be inferred from the ECNI
spectra except fragment ions corresponding to the successive
loss of chlorines.
The molecular ion of the unknown phenolic compound
was discovered by EI-MS. The low-resolution EI spectrum
indicated that the molecular ion was a heptachlorinated
species (Figure 2b). The [M]+ of 372 amu corresponded to
[C9H3Cl7O]+, which was most consistent with a MeO-HpCS
isomer. In Figure 2, fragments are labeled for loss of mass
units and their corresponding structures based on this
assignment. The EI spectrum showed the distinctive loss of
a methyl group, a chlorine, and an [M - 43]+ ion, which
represented an [M - CH3CO]+ fragment ion. All these
fragmentation patterns have been observed previously for
MeO-PCBs (27). The [M - CH3CO]+ fragment is indicative
of a para-substituted, aromatic compound when accompa-
nied by an [M - CH3]+ fragment (28). The fragmentation is
thought to entail a two-step processsthe loss of a methyl
radical followed by the loss of carbon monoxide and
subsequent formation of a nonaromatic cyclopentadienyl
ring. The formation of a [M - 43]+ ion was demonstrated
previously for polymethoxybiphenyls (29). Para-substitution
of the aromatic ring was the only molecular structure that
allows for charge delocalization to the ethylene side chain
and electronic stabilization of the proposed [M - CH3]+
fragment ion. The [M - CH3CO]+ fragment is stabilized by
charge delocalization through conjugation of the cyclopen-
FIGURE 1. Electron-capture negative ionization mass spectra (fullscan) chromatogram of the phenolic compound fraction from polar bear
plasma. The compounds have been methylated but are shown as hydroxylated precursors.
FIGURE 2. Low resolution (A) electron-capture negative ionization
(200-400 amu) and (B) electron impact (290-400 amu) ionization
mass spectra of the unknown methylated phenolic compound
isolated from polar bear plasma (see Figure 1).
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tadienyl group to the ethylene side chain and may be further
stabilized by forming a heptachlorotropylium cation.
The elemental composition of the molecular ion and the
first four major ion clusters in the EI spectrum (Figure 2b)
were confirmed using high-resolution EI-MS. The most
probable elemental compositions were calculated by software
provided as part of the OPUS operating system of the VG
AutoSpec using the technique described by Tittlemier et al.
(23). The exact mass of the molecular ion and fragments of
the unknown compound were compared relative to the most
probable theoretical compositions (Table 1). The mass
differences between the theoretical masses and those of the
unknown compound agreed to within 3½ or better, con-
firming that the molecular formula was C9H3OCl7, and that
the first three fragment ions in the EI spectrum resulted from
a loss of CH3, Cl, and CH3CO.
The molecular formula is indicative of a compound with
five units of unsaturation. In conjunction with the low
molecular weight, this suggests a chlorinated monocyclic
aromatic compound. A benzene ring accounts for four units
of unsaturation, leaving the fifth unit of unsaturation to reside
in a side chain double bond. The molecule has seven chlorine
atoms and must contain a methoxy substituent. Thus, the
most likely structure is a MeO-HpCS isomer. The para
position is the most likely position on the phenyl ring for a
hydroxyl group according to the mass spectrometry data.
This position is also the most common location for the OH-
group in OH-PCB compounds retained in plasma (1, 5, 6).
Synthesis of 4-Hydroxyheptachlorostyrene and Con-
firmation of Unknown Compound Identity. Based on the
mass spectral evidence, it was probable that the unknown
compound was 4-OH-HpCS, which has not been reported
previously in the literature. Therefore, synthesis of 4-OH-
HpCS was carried out.
N-Butyllithium in tetrahydrofuran was reacted with
2,3,5,6-tetrachloroanisole at -78 °C to generate the 4-meth-
oxy-2,3,5,6-tetrachlorophenyllithium. This was reacted im-
mediately with chloral and allowed to warm to room
temperature to generate the 4-methoxyheptachlorostyrene
oxide. The yield for the reaction was approximately 31% after
preparative thin-layer chromatography (TLC, silica gel, 25%
dichloromethane/hexanes) which was applied to remove the
remaining tetrachloroanisole and a pentachloroanisole im-
purity. The 4-methoxyheptachlorostyrene oxide was treated
with excess phosphorus pentachloride (1.5-2.0 equiv) in
dichloromethane and allowed to react overnight at room
temperature. The products of the reaction included 4-(1,2,2,2-
tetrachloroethyl)-2,3,5,6-tetrachloroanisole and MeO-HxCS.
This mixture was heated for 4 h on a steam bath with 1 equiv
of 1,5-diaza[5.4.0]undecane in acetonitrile to give 4-MeO-
HpCS and two other impurities. The MeO-HxCS was no
longer detected. 4-MeO-HpCS was isolated by TLC and
demethylated by refluxing with excess boron tribromide (6-7
equiv, 1 M in dichloromethane) in 1,2-dichloroethane for 20
h. The resulting compound, 4-OH-HpCS, was separated from
unreacted 4-MeO-HpCS using preparative TLC. The final
purity of 4-OH-HpCS was greater than 99%.
Low-resolution EI and ECNI spectra for the 4-OH-HpCS
were identical to those determined in the polar bear plasma
samples (Figure 2). Furthermore, the exact mass assignments
agreed with the unknown compound within 3½ amu (Table
1). The retention time of the standard and the unknown
compound were then compared relative to the retention time
of a major OH-PCB in polar bear plasma (4-OH-2,2',3,4',5,5',6-
heptachlorobiphenyl) on three different GC columns of
varying polarity. The relative retention time of the standard
and compound present in the samples matched within
experimental error on all three columns (Table 2).
The unknown phenolic compound in polar bear plasma
was therefore confirmed to be 4-OH-HpCS.
Transthyretin (TTR) Determination in Polar Bear Plasma
and Binding Affinity of 4-OH-HpCS to Human TTR. TTR is
a thyroid transport protein that is highly conserved among
most mammals, birds, and some reptiles (30). To confirm
that polar bears possess TTR, polar bear plasma proteins (N
) 4) were separated by PAGE, as described previously by
Brouwer and van den Berg (4). Determination of 125I-T4-
competitive binding to specific proteins was performed as
described by Lans et al. (31) and Darnerud et al. (32). Plotting
125I-T4-radioactivity against migration distance on the gel
made the PAGE gel profile shown in Figure 3.
Three peaks showing TTR-bound radioactivity were
identified in polar bear plasma after PAGE (Figure 3).
Identification of the peaks was based on comigration of the
reference proteins and by comparing Rf-values (i.e. the
position of a protein on the gel (in mm) divided by the position
of the front of the gel (in mm)) of the peaks containing
radioactivity with Rf-values of reference samples. Rf-values
of the two peaks containing radioactivity (Rf ) 0.45-0.49
and 0.62-0.63) are in accordance with Rf-values of the
reference proteins, bovine serum albumin (Rf ) 0.41-0.42)
and human TTR (0.59-0.61), respectively. Thus, polar bears
likely possess TTR. The last peak in Figure 3 represents free
T4. As with other mammals, albumin is also present in polar
bear plasma, and binding of T4 with albumin is higher than
with TTR.
OH-PCBs have been shown to bind with high affinity to
TTR and not other thyroid hormone transport proteins, such
as thyroxine binding globulin (11, 33). Most OH-PCB
congeners detected in plasma have an OH-group in the para-
position relative to the phenyl-phenyl bond and have
adjacent chlorines in both meta-positions (1, 5, 6). Since
4-OH-HpCS is structurally similar to other chlorinated
TABLE 1. Elemental Compositions Derived from High Resolution EI-MS of the Four Major Ions (See Figure 2) of the Methylated
Unknown Phenolic Compound and the Methylated 4-OH-HpCS Synthesized Standarda
sample standard
fragment
most probable
elemental composition theoretical mass exptl mass difference exptl mass difference
M¥+ C9H3OCl7 371.8004 371.7999 0.0005 371.7976 0.0027
[M - 15]+ C8OCl7 356.7769 356.7802 -0.0033 356.7762 0.0007
[M - 35]+ C9H3OCl6 336.8315 336.8323 -0.0008 336.8303 0.0012
[M - 43]+ C7Cl7 328.7833 328.7863 -0.0029 328.7820 0.0014
a The sample and standard were analyzed at a resolution of 10 000.
TABLE 2. Retention Times of 4-OH-HpCS on Three Different GC
Columns Relative to the Retention Time of
4-OH-2,2',3,4',5,5',6-Heptachlorobiphenyl, One of the Major
OH-PCBs in Polar Bear Plasma (See Figure 1)
relative retention time
GC column standard sample difference
DB-5 0.7239 0.7245 -0.0006
DB-1701 0.6075 0.6079 -0.0004
Rtx-2330 0.5914 0.5923 -0.0009
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phenolics that bind with high affinity to TTR and TTR was
found in polar bear plasma, it was of interest to determine
the relative binding affinity of 4-OH-HpCS and T4 to TTR.
The assay for determining competitive binding of 4-OH-
HpCS and 125I-labeled T4 to human TTR was performed as
described elsewhere (31). Concentration-dependent, com-
petitive binding curves of T4 and 4-OH-HpCS relative to 125I-
T4 (% of control) for TTR protein are shown in Figure 4.
IC50 values (concentration of competitor at half-maximal
specific binding) and relative binding affinities (RBA) were
calculated as described by Meerts et al. (13). RBA was
calculated by dividing the IC50 of T4 by the IC50 of 4-OH-
HpCS. The competitive binding assay was done in duplicate,
and within the assay each concentration was tested in
triplicate.
The RBA and IC50 values of 4-OH-HpCS were 3.96  107
M-1 and 71.74 nM, respectively. The relative potency of 4-OH-
HpCS versus T4 for TTR binding was 1.1. This is within the
range of potencies of other halogenated phenolic compounds
reviewed by Brouwer et al. (8) and Brucker-Davis (34) and
indicates that circulating levels of 4-OH-HpCS in blood have
the potential to disrupt thyroid hormone transport and
possibly retinol transport in vivo. The displacement of the
natural ligand (T4) from TTR by halogenated phenolic
compounds is hypothesized to result in an increased clear-
ance of plasma T4 in vivo. This has been observed in animals
exposed to PHAHs, such as PCBs (32) or OH-PCBs (3). In
another example, Sinjari et al. (35) demonstrated that
administration of 4'-OH-3,3',4,5'-tetrachlorobiphenyl and
4-OH-2,3,3',4',5-pentachlorobiphenyl to pregnant mice re-
duced total T4 levels in both maternal and fetal plasma.
Concentrations of 4-OH-HpCS Compared to Other
Chlorinated Phenolic Compounds, OCS and PCBs. Thirty
polar bear plasma samples (3-5 g) were analyzed for
chlorinated phenolic compounds, PCBs and OCS. The polar
bears included both males and females (15 each) and ranged
from 1 to 27 years of age. Mean recoveries of the 13C-labeled
OH-PCBs, PCBs, and PCP were 102% ( 9%, 99 ( 19%, and
110 ( 9% CV, respectively. Therefore, recovery correction
was not required. The total concentration of chlorinated
phenolic compounds was calculated from the sum of OH-
PCBs (“OH-PCBs, 37 congeners), PCP, and 4-OH-HpCS.
“PCBs comprised the sum of 23 congeners (17). The OH-
PCB data is presented only to illustrate the significance of
the 4-OH-HpCS with respect to the other major chlorinated
phenolic compounds. Further interpretation of the OH-PCBs
found in polar bear plasma will be discussed in another
publication.
Concentrations of 4-OH-HpCS, “OH-PCBs, PCP, OCS,
CB153, and “PCBs in polar bear plasma are listed in Table
3. Plasma concentrations of 4-OH-HpCS were on average 39
times higher than OCS, although the ratio of 4-OH-HpCS to
OCS ranged from 5.19 to 216. The mean ratio of 4-OH-HpCS
to CB153 was 0.712 (( 0.580 SD), indicating that 4-OH-HpCS
is one of the main contaminants in polar bear plasma.
Concentrations of 4-OH-HpCS constituted on average
12.2% of the total concentration of chlorinated phenolic
compounds in polar bear plasma, the remainder being almost
entirely OH-PCBs (Table 3, Figure 1). 4-OH-HpCS was similar
in concentration to the major OH-PCB congeners. The
concentration of “phenolics was ca. twice that of “PCBs and
is likely caused by the high binding affinity of the phenolics
to plasma proteins. PCP was a small percentage of total
chlorinated phenolics, unlike humans, where it is frequently
the most important contributor (5).
Evidence for Bioaccumulation and Metabolism of OCS
as a Source of 4-OH-HpCS in the Polar Bear Food Chain.
Long-range transport from source regions and bioaccumu-
lation of 4-OH-HpCS in the polar bear food chain is not
likely. First, chlorophenols generally have high water solubility
and low volatility. Therefore, they would be prone to remain
in areas close to sources (36). Halogenated phenols have not
been reported in any Arctic biota (37). Second, phenolic
compounds are readily conjugated and excreted in many
higher organisms and are not expected to biomagnify in
mammalian food chains (38). Thus, the most probable
sources of 4-OH-HpCS are through metabolism of OCS or
a heptachlorostyrene (HpCS) congener.
Isomers of HpCS with unknown chlorine substitution
pattern have been reported in the literature at levels 10-fold
less than OCS in the Elbe river in Germany and the Great
Lakes where OCS contamination is relatively high (39, 40).
HpCS isomers have never been observed in Arctic biota and
are unlikely sources of 4-OH-HpCS. There can be little doubt
that 4-OH-HpCS in polar bear plasma results from CYP450-
mediated metabolism of OCS.
OCS was identified in polar bears as part of another study
but not reported (18, 20). To compare relative accumulation
of OCS and CB-153 in plasma with that in adipose tissue and
liver, concentrations of OCS and CB-153 from these previous
studies were reexamined. A description of analytical methods
and concentrations of PCBs, DDE, and their methylsulfonyl-
PCB metabolites in polar bear adipose tissue and liver are
given in Letcher et al. (19, 20). OCS concentrations, which
were simultaneously quantitated by GC/EI-MS in that study,
are reported in Table 4. OCS was found to be a relatively
minor contaminant in liver and adipose tissue, as was the
case for plasma. Tissue-specific accumulation of OCS oc-
curred in liver since the ratio of OCS to CB-153 in polar bear
liver was four times that of fat (p < 0.001). The ratio of OCS
to CB-153 in liver was nearly identical to that in plasma of
FIGURE 3. Separation by polyacrylamide gel electrophoresis (PAGE)
and radioactive detection of proteins in polar bear plasma after
incubation with 125I-thyroxine (T4).
FIGURE 4. The concentration-dependent, competitive binding of
4-hydroxyheptachlorostyrene (4-OH-HpCS) and thyroxine (T4) relative
to 125I-T4 for human transthyretin (TTR). Assays were performed in
duplicate.
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bears from the same area (Table 3). Given the high variance
in the ratios, this finding is probably a coincidence. Nev-
ertheless, it suggests that plasma concentrations of OCS
relative to CB153 in polar bears are reflective of other tissues.
Five ringed seal plasma samples (3-7 g) were analyzed
as described above, and the results are shown in Table 3.
Mean recoveries of the 13C-labeled OH-PCBs, PCBs, and PCP
were 110% ( 8%, 74 ( 4%, and 71 ( 10% CV, respectively.
The ringed seals were sampled from a region that is a
considerable distance from where the polar bear samples
were taken. However, differences in patterns and concentra-
tions of PHAHs (including PCBs) in seals and bears between
these areas has been determined to be relatively small (17,
41). Therefore, geographical differences in contamination
are not expected to influence the comparison between
species.
Concentrations of 4-OH-HpCS were 147 times lower in
seals than in polar bears even though OCS plasma concen-
trations were only slightly lower in seals. In seals, 4-OH-
HpCS constituted 17.6% of the total concentration of the
chlorinated phenolic compounds, which was similar to the
polar bear samples (12.2%). The ratio of 4-OH-HpCS to OCS
was 150 times lower in seal than in polar bear. Assuming that
that 4-OH-HpCS has similar binding affinities for TTR in
both the polar bear and ringed seal, the ratio of 4-OH-HpCS
to OCS indicates that seals are capable of metabolizing OCS
to 4-OH-HpCS but at a much slower rate than polar bears.
The mean concentration of total phenolic compounds was
272 times lower in seals than bears. These findings support
previous data that showed ringed seals have a lower capability
to metabolize PHAHs (20).
Despite a large difference in ratios of 4-OH-HpCS to
OCS, the mean ratio of OCS to CB153 was only three times
higher for seal than polar bear. This suggests that while
formation/retention of 4-OH-HpCS is much more rapid in
bears than in seals, it is still slow compared to net bioac-
cumulation of OCS in the bear. The situation is similar to
that for PCBs. Most of the major OH-PCBs in human plasma
are believed to be formed by metabolism of highly recalcitrant
PCBs, such as CB118, CB138, and CB153, but this rate of
metabolism is insignificant compared to rate of accumulation
and loss by other mechanisms, such as partitioning into fecal
matter (6).
Discussion
OCS is an industrial byproduct. The major source of OCS is
thought to involve electrolysis of salt solutions using a car-
bon electrode, especially in the production of sodium
hydroxide and chlorine from sodium chloride (42). Other
possible sources include emissions from the purification of
aluminum with gaseous chlorine in graphite vessels (43)
and industrial processes involving the electrolysis of mag-
nesium chloride (44). OCS is generally a low-level environ-
mental contaminant that is usually considered to be of
little significance compared to major persistent PHAHs,
especially PCBs. Although there are few publications that
report OCS concentrations, it is a global contaminant found
in arctic fish (45) and Antarctic seabirds (46). OCS has been
found to accumulate to high concentrations in fish from the
Frierfjord in Norway (45) and the Great Lakes (40), close to
local sources.
OCS is not a major PHAH in Arctic marine food webs (37).
Therefore, the relatively high concentration of 4-OH-HpCS
in polar bear plasma compared to other phenolic compounds
(mainly OH-PCBs) as well as other major contaminants (such
as CB153) was unexpected. The presence of 4-OH-HpCS in
polar bear and ringed seal plasma is most reasonably
explained by metabolism of OCS. At least in some species at
higher trophic levels, the findings from the present study
suggest that the significance of OCS as an environmental
contaminant may have been underestimated.
Phenolic compounds appear to be mainly retained in
plasma, and thus bioaccumulation of 4-OH-HpCS from seal
to bear is not an influencing factor, since seal fat, not blood,
is the important component in the polar bear diet. The
concentrations of 4-OH-HpCS and the relative concentrations
to CB153 and OCS were much lower in ringed seal relative
to polar bear plasma. This is probably because of lower
capacity of seals to metabolize PHAHs (20). OCS/CB153 ratios
were similar in plasma of the two species, suggesting that
rate of formation of 4-OH-HpCS in the polar bear is not fast
compared to the rate of accumulation of OCS from the diet.
The apparent anomaly of relatively high levels of metabolites
of slowly metabolized PHAHs in plasma presumably occurs
because of specific and high binding affinity of the metabo-
lites to plasma proteins (6). If this binding is strong enough,
it will compete with conjugation and excretion mechanisms
in liver and kidney. Thus, the metabolites are effectively
transferred into the plasma compartment and protected from
excretion.
TABLE 3. Plasma Concentrations (ng/g Wet Weight) and Selected Mean Ratios of Concentrations of Chlorinated Phenolic
Compounds, Including 4-Hydroxyheptachlorostyrene (4-OH-HpCS) and Related PHAHs in Polar Bear Plasma (N ) 30) from the
Resolute Bay Area, Nunavut Territory, Canada and Ringed Seal Plasma (N ) 5) from Kuujjuaq, Que´bec, Canada
polar bear plasma ringed seal plasma
mean min. max. SD mean SD
4-OH-HpCS 9.11 2.89 22.9 3.85 0.062 0.023
PCP 0.210 0.093 0.531 0.099 0.237 0.136
“ OH-PCBs 92.6 26.4 576 117 0.081 0.042
“ phenolics 103 33.2 600 120 0.379 0.181
OCS 0.348 0.106 0.940 0.188 0.266 0.086
CB 153 20.2 4.81 82.0 16.3 5.16 3.71
“ PCBs 46.9 16.1 161 32.3 27.1 16.5
4-OH-HpCS/
“ phenolics
0.122 0.038 0.248 0.053 0.176 0.077
4-OH-HpCS/OCS 39.2 5.19 216 41.2 0.260 0.124
4-OH-HpCS/CB153 0.712 0.035 2.43 0.580 0.016 0.009
OCS/CB153 0.024 0.005 0.078 0.018 0.072 0.042
TABLE 4. Mean Concentrations of CB153 and
Octachlorostyrene (OCS) (ng/g Lipid Weight) and Mean Ratios
in Polar Bear Liver and Adipose Samples (Mean ( SD)
sample
tissue size OCS CB-153
ratio
OCS:CB-153
polar bear
adipose
8 14 ( 12 2670 ( 640 0.005 ( 0.005
polar bear
liver
8 156 ( 115 6840 ( 3120 0.022 ( 0.008
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TTR is assumed to be the main plasma protein responsible
for specific binding of phenolic compounds found in plasma,
because most of the compounds, including 4-OH-HpCS, have
a similar structure to the natural ligand, T4 (31). We
demonstrated that TTR was present in polar bear plasma, so
binding to this protein is a plausible explanation for the
relatively high levels of 4-OH-HpCS in these species.
The binding affinity of 4-OH-HpCS to human TTR was
about the same as T4. However, several OH-PCBs, PCP, and
even PCBs, such as CB153 (47), have been shown to bind
with even greater relative binding affinity then T4 (10, 11).
Little is known about differences in binding affinity of T4 or
metabolites of PHAHs to TTR among species except for
humans and laboratory animals. Nor is anything known if
other proteins, such as albumin, are participating in plasma
binding of these compounds in some species. Therefore, it
is unclear how important a role TTR plays in maintaining
high concentrations of halogenated phenolic compounds or
in the transport of T4, in the plasma of mammals. These are
important factors in understanding possible disruption of
thyroid hormone and retinol homeostasis. We are presently
studying the effects of contaminants and their metabolites
on circulating thyroid hormone and vitamin A levels in the
polar bear as well as the distribution of 4-OH-HpCS in plasma
of other species, to help resolve some of these questions.
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